Show simple item record

dc.contributor.authorTan, A
dc.contributor.authorCosti, S
dc.contributor.authorMorris, LS
dc.contributor.authorVan Dam, NT
dc.contributor.authorKautz, M
dc.contributor.authorWhitton, AE
dc.contributor.authorFriedman, AK
dc.contributor.authorCollins, KA
dc.contributor.authorAhle, G
dc.contributor.authorChadha, N
dc.contributor.authorDo, B
dc.contributor.authorPizzagalli, DA
dc.contributor.authorIosifescu, D
dc.contributor.authorNestler, EJ
dc.contributor.authorHan, M-H
dc.contributor.authorMurrough, JW
dc.date.accessioned2020-12-14T05:27:32Z
dc.date.available2020-12-14T05:27:32Z
dc.date.issued2020-06-01
dc.identifierpii: 10.1038/s41380-018-0283-2
dc.identifier.citationTan, A., Costi, S., Morris, L. S., Van Dam, N. T., Kautz, M., Whitton, A. E., Friedman, A. K., Collins, K. A., Ahle, G., Chadha, N., Do, B., Pizzagalli, D. A., Iosifescu, D., Nestler, E. J., Han, M. -H. & Murrough, J. W. (2020). Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder. MOLECULAR PSYCHIATRY, 25 (6), pp.1323-1333. https://doi.org/10.1038/s41380-018-0283-2.
dc.identifier.issn1359-4184
dc.identifier.urihttp://hdl.handle.net/11343/253925
dc.description.abstractMajor depressive disorder (MDD) is a leading cause of disability worldwide, yet current treatment strategies remain limited in their mechanistic diversity. Recent evidence has highlighted a promising novel pharmaceutical target-the KCNQ-type potassium channel-for the treatment of depressive disorders, which may exert a therapeutic effect via functional changes within the brain reward system, including the ventral striatum. The current study assessed the effects of the KCNQ channel opener ezogabine (also known as retigabine) on reward circuitry and clinical symptoms in patients with MDD. Eighteen medication-free individuals with MDD currently in a major depressive episode were enrolled in an open-label study and received ezogabine up to 900 mg/day orally over the course of 10 weeks. Resting-state functional magnetic resonance imaging data were collected at baseline and posttreatment to examine brain reward circuitry. Reward learning was measured using a computerized probabilistic reward task. After treatment with ezogabine, subjects exhibited a significant reduction of depressive symptoms (Montgomery-Asberg Depression Rating Scale score change: -13.7 ± 9.7, p < 0.001, d = 2.08) and anhedonic symptoms (Snaith-Hamilton Pleasure Scale score change: -6.1 ± 5.3, p < 0.001, d = 1.00), which remained significant even after controlling for overall depression severity. Improvement in depression was associated with decreased functional connectivity between the ventral caudate and clusters within the mid-cingulate cortex and posterior cingulate cortex (n = 14, voxel-wise p < 0.005). In addition, a subgroup of patients tested with a probabilistic reward task (n = 9) showed increased reward learning following treatment. These findings highlight the KCNQ-type potassium channel as a promising target for future drug discovery efforts in mood disorders.
dc.languageEnglish
dc.publisherNATURE PUBLISHING GROUP
dc.titleEffects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder
dc.typeJournal Article
dc.identifier.doi10.1038/s41380-018-0283-2
melbourne.affiliation.departmentMelbourne School of Psychological Sciences
melbourne.source.titleMolecular Psychiatry
melbourne.source.volume25
melbourne.source.issue6
melbourne.source.pages1323-1333
melbourne.elementsid1355520
melbourne.openaccess.urlhttp://europepmc.org/articles/pmc6494706?pdf=render
melbourne.openaccess.statusAccepted version
melbourne.contributor.authorVan Dam, Nicholas
dc.identifier.eissn1476-5578
melbourne.accessrightsAccess this item via the Open Access location


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record